Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...

The entrance to the Rolls Building, which houses the Business and Property Courts of England and Wales. A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ...

Niraparib is under clinical development by GSK and currently in Phase II for Hypopharyngeal ... role in drug-specific PTSR and likelihood of approval. Niraparib (MK-4827, Zejula) is an anti-neoplastic ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

If approved, we expect TIVDAK to add to ZEJULA and augment our commercial franchise in women’s tumors.” “There are approximately 150,000 new cases of cervical cancer annually in China 1 ...

Key stocks in focus include General Insurance Corp, ONGC, SpiceJet, GSK Pharma, and Cipla due to various developments. Notable updates include the government's stake sale in General Insurance Corp and ...